Phase 2 N=40 A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease
Graft vs Host Disease
Primary: Percentage of Patients That Respond to Treatment — 65 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia
Encephalopathy, Hypoxic-Ischemic
Primary: Steady State Clonidine Blood Levels During Hypothermia — 0.6 ng/ml
Phase 2 N=3 An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
Mucopolysaccharidosis Type 7
Primary: Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan Sulfate — -50.41; -38.94; -63.49; -51.82 percentage change
Phase 2 N=130 A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Leukemia
Primary: Major Cytogenetic Response (MCyR) Rate — 89.7 percentage of participants
Phase 2 N=23 A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Advanced Hepatocellular Carcinoma · HCC · Liver Cancer
Primary: Time to Disease Progression — 8 months
Phase 2 N=68 Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
Breast Cancer
Primary: Change in Bone Mineral Density (BMD) From Baseline to 1 Year — 0.048; 0.007; 0.014; 0.005 grams per cubic centimeter
Phase 2 N=90 Sitagliptin for Reducing Inflammation and Immune Activation
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 15/16 — -0.03; -0.03 log10 pg/mL — p=1.000
Phase 2 N=3,013 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
Virus Diseases
Primary: Number of Subjects With Solicited Local Adverse Events — 356; 57; 3; 0 Participants
Phase 2 N=319 Bay98-7196, Dose Finding / POC Study
Endometriosis
Primary: Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days…
Phase 2 N=602 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Six Minute Walk Distance (6MWD) at Week 4, 12 and 24 — 314.4; 311.8; 313.2; 319.9 Meter (m) — p=0.517
Phase 2 N=84 Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
HIV-1 Infection
Primary: Etonogestrel Concentrations at Study Day 21 — 1860.00; 429.00; 3290.00 pg/mL — p=<0.001
Phase 2 N=64 Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Chronic Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Responder Rate (RR) to Avatrombopag on Day 28 — 13.3; 53.3; 50.0; 80.0 Percentage of participants
Phase 2 N=131 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
Cystitis, Interstitial · Painful Bladder Syndrome
Primary: Change From Baseline in Daily Average Bladder Pain to Treatment 1 Week 4 Follow-up — -1.2; -1.5 score on a scale — p=0.505
Phase 2 N=61 Heart Rate Variability in Response to Metformin Challenge
Fibromyalgia · Mitochondrial Diseases · Movement Disorders
Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77
Phase 2 N=444 A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 12.2; 3.6; 16.4; 7.5 % of patients evaluable for response